Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead

Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030

Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.

Investors Business Daily

Buy, Hold or Sell? Gilead Sciences Inc. (GILD) and Moderna Inc. (MRNA)

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

StockNews.com

Gilead Stock Dives As Light Profit Overshadows Strong Cancer Drug Sales

Biotech giants Gilead Sciences and Amgen posted mixed quarters on Thursday — leading GILD stock and Amgen stock to topple.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade

High volatility means higher-than-normal option premiums, which can be great for option sellers.

Investors Business Daily

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

StockNews.com

2 Dividend Stocks That Could Pay You for the Rest of Your Life

As the market remains volatile due to ongoing concerns about elevated inflation, prolonged rate hikes, and an impending recession, fundamentally strong dividend stocks Bristol-Myers Squibb (BMY) Gilead Sciences (GILD) might be ideal buys to ensure a stable income stream. Moreover, these stocks could be great long-term investments. Read more.

StockNews.com

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years

Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.

Investors Business Daily

At buzzy health care business conference, investors fear the bubble will burst

JPMorgan's cheery confab returned to San Francisco, but the health care capitalists had economic anxiety, too.

WEKU

Health care investors convene in SF

Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab

Salon

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

StockNews.com

2 Biotech Stocks to Buy Amid a Blazing Hot Run

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

StockNews.com

Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot

Gilead won Food and Drug Administration approval for a twice-a-year HIV treatment called Sunlenca on Thursday.

Investors Business Daily

Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

Investors Business Daily

Moderna Stock Breaks Out As Cancer Vaccine Shows Promise In Keytruda Tie-Up

Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results sent Moderna shares soaring.

Investors Business Daily

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.

Investors Business Daily

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch

Gilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The oncology business is growing bullishly.

The Guardian - UK

The week in TV: Brian Cox: How the Other Half Live; I’m a Celebrity…; 1899; Hong Kong’s Fight for Freedom and more

The Succession star rages against inequality; all aboard Netflix’s Victorian steamship horror; Hongkongers turn to violence; and The Handmaid’s Tale is back on track

StockNews.com

1 Stock to Buy This Week Following Its Recent Earnings Beat

Biopharmaceutical giant Gilead Sciences (GILD) reported better-than-expected third-quarter earnings and sales and raised its full-year guidance. Analysts see immense growth potential in the company’s HIV and oncology franchises, which should boost its performance in the upcoming quarters. Given its strong earnings, high profitability, discounted valuation, and attractive dividend, we think…

Investors Business Daily

Gilead Breaks Out In Bullish Volume As Its Cancer Drug Sales Nearly Double

Gilead Sciences reported 79% growth for its cancer drugs, helping beat expectations. On Friday, GILD stock broke out.

The Independent UK

It’s time for June Osborne to start winning in The Handmaid’s Tale

‘The Handmaid’s Tale’, returning to Channel 4 this weekend, has spent four seasons dragging June into the depths of hell. There’s nothing more to be learnt from her suffering, writes Amanda Whiting

Reuters

U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak

The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.

Benzinga

Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29

Reuters

1 … 4 5 6 7

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.